User:Indefensible/Draft/Beam Therapeutics

Beam Therapeutics is an American biotechnology company based in Cambridge, Massachusetts in the fields of gene therapy and genome editing using CRISPR and prime editing technologies, whereby DNA sequences can be modified even more precisely compared to previous methods.

History
Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang. Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million. The first clinical trials for therapies are expected in 2021.